LT4121007T - Antikūnų prieš beta amiloido peptido protofibriles didelės koncentracijos preparatai ir jų naudojimo būdai - Google Patents
Antikūnų prieš beta amiloido peptido protofibriles didelės koncentracijos preparatai ir jų naudojimo būdaiInfo
- Publication number
- LT4121007T LT4121007T LTEPPCT/IB2021/000155T LTIB2021000155T LT4121007T LT 4121007 T LT4121007 T LT 4121007T LT IB2021000155 T LTIB2021000155 T LT IB2021000155T LT 4121007 T LT4121007 T LT 4121007T
- Authority
- LT
- Lithuania
- Prior art keywords
- preparations
- methods
- high concentration
- antibodies against
- amyloid peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992746P | 2020-03-20 | 2020-03-20 | |
| US202063027263P | 2020-05-19 | 2020-05-19 | |
| PCT/IB2021/000155 WO2021186245A1 (en) | 2020-03-20 | 2021-03-19 | HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT4121007T true LT4121007T (lt) | 2025-09-25 |
Family
ID=75746958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/IB2021/000155T LT4121007T (lt) | 2020-03-20 | 2021-03-19 | Antikūnų prieš beta amiloido peptido protofibriles didelės koncentracijos preparatai ir jų naudojimo būdai |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20230183328A1 (lt) |
| EP (2) | EP4121007B1 (lt) |
| JP (2) | JP7689141B2 (lt) |
| KR (1) | KR20220156534A (lt) |
| CN (1) | CN115315251A (lt) |
| AU (1) | AU2021238951A1 (lt) |
| BR (1) | BR112022018766A2 (lt) |
| CA (1) | CA3174778A1 (lt) |
| CL (2) | CL2022002517A1 (lt) |
| CO (1) | CO2022012916A2 (lt) |
| DK (1) | DK4121007T3 (lt) |
| ES (1) | ES3041762T3 (lt) |
| FI (1) | FI4121007T3 (lt) |
| HR (1) | HRP20251087T1 (lt) |
| HU (1) | HUE072937T2 (lt) |
| IL (2) | IL326613A (lt) |
| LT (1) | LT4121007T (lt) |
| MA (1) | MA59082B1 (lt) |
| MD (1) | MD4121007T2 (lt) |
| MX (1) | MX2022011101A (lt) |
| PH (1) | PH12022552172A1 (lt) |
| PL (1) | PL4121007T3 (lt) |
| PT (1) | PT4121007T (lt) |
| RS (1) | RS67249B1 (lt) |
| SI (1) | SI4121007T1 (lt) |
| SM (1) | SMT202500350T1 (lt) |
| WO (1) | WO2021186245A1 (lt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| EP4367516A1 (en) | 2021-07-09 | 2024-05-15 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| MX2024009492A (es) | 2022-02-02 | 2024-08-09 | Eisai R&D Man Co Ltd | Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181). |
| TW202430554A (zh) | 2022-11-28 | 2024-08-01 | 日商衛材R&D企管股份有限公司 | 使用ｔａｕ ＰＥＴ水平之治療方法 |
| WO2024254542A1 (en) | 2023-06-09 | 2024-12-12 | Eisai R&D Management Co., Ltd. | Methods of treatment using an anti-abeta protofibril antibody |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| IL272773B2 (en) | 2017-08-22 | 2024-06-01 | Biogen Ma Inc | Pharmaceutical preparations containing anti-amyloid cell antibodies |
| MX2021000778A (es) * | 2018-07-24 | 2021-03-31 | Eisai R&D Man Co Ltd | Metodos de tratamiento y prevencion de la enfermedad de alzheimer. |
-
2021
- 2021-03-19 KR KR1020227030919A patent/KR20220156534A/ko active Pending
- 2021-03-19 HR HRP20251087TT patent/HRP20251087T1/hr unknown
- 2021-03-19 BR BR112022018766A patent/BR112022018766A2/pt unknown
- 2021-03-19 MA MA59082A patent/MA59082B1/fr unknown
- 2021-03-19 LT LTEPPCT/IB2021/000155T patent/LT4121007T/lt unknown
- 2021-03-19 JP JP2022556091A patent/JP7689141B2/ja active Active
- 2021-03-19 IL IL326613A patent/IL326613A/en unknown
- 2021-03-19 EP EP21722538.2A patent/EP4121007B1/en active Active
- 2021-03-19 EP EP23179487.6A patent/EP4252777A3/en active Pending
- 2021-03-19 FI FIEP21722538.2T patent/FI4121007T3/fi active
- 2021-03-19 CA CA3174778A patent/CA3174778A1/en active Pending
- 2021-03-19 AU AU2021238951A patent/AU2021238951A1/en active Pending
- 2021-03-19 MD MDE20230104T patent/MD4121007T2/ro unknown
- 2021-03-19 WO PCT/IB2021/000155 patent/WO2021186245A1/en not_active Ceased
- 2021-03-19 SM SM20250350T patent/SMT202500350T1/it unknown
- 2021-03-19 HU HUE21722538A patent/HUE072937T2/hu unknown
- 2021-03-19 IL IL295383A patent/IL295383B1/en unknown
- 2021-03-19 ES ES21722538T patent/ES3041762T3/es active Active
- 2021-03-19 MX MX2022011101A patent/MX2022011101A/es unknown
- 2021-03-19 PT PT217225382T patent/PT4121007T/pt unknown
- 2021-03-19 DK DK21722538.2T patent/DK4121007T3/da active
- 2021-03-19 PH PH1/2022/552172A patent/PH12022552172A1/en unknown
- 2021-03-19 CN CN202180019180.6A patent/CN115315251A/zh active Pending
- 2021-03-19 RS RS20250922A patent/RS67249B1/sr unknown
- 2021-03-19 PL PL21722538.2T patent/PL4121007T3/pl unknown
- 2021-03-19 US US17/906,660 patent/US20230183328A1/en active Pending
- 2021-03-19 SI SI202130347T patent/SI4121007T1/sl unknown
-
2022
- 2022-09-12 CO CONC2022/0012916A patent/CO2022012916A2/es unknown
- 2022-09-14 CL CL2022002517A patent/CL2022002517A1/es unknown
-
2024
- 2024-11-08 CL CL2024003428A patent/CL2024003428A1/es unknown
-
2025
- 2025-04-10 JP JP2025064827A patent/JP2025111516A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT4121007T (lt) | Antikūnų prieš beta amiloido peptido protofibriles didelės koncentracijos preparatai ir jų naudojimo būdai | |
| IL288755A (en) | Compositions and methods for biological delivery vehicles | |
| DK4232463T3 (da) | Interleukin-2-fc-fusionsproteiner og fremgangsmåder til anvendelses | |
| EP3962941A4 (en) | RECOMBINANT POLYCLONAL PROTEINS AND METHODS OF USE THEREOF | |
| IL285270A (en) | Compositions and methods for treating neurocognitive disorders | |
| IL277337A (en) | Antibodies against alpha signal modulatory protein and methods of use | |
| IL286132A (en) | Human carbonic anhydrase 2 compositions and methods for tunable regulation | |
| IL281082A (en) | Compositions of cxcr4 inhibitors and methods of preparation and use | |
| IL284683A (en) | Acute treatment and rapid treatment of headache using anti-cgrp antibodies | |
| HUE065544T2 (hu) | Emberi anti-rankl ellenanyagok készítményei és eljárások alkalmazásukra | |
| LT4200018T (lt) | Anti-par-2 antikūnai ir jų panaudojimo būdas | |
| IL272253A (en) | Compositions and methods for treatment of inflammatory conditions and diseases of the skin | |
| KR20240101677A9 (ko) | Dickkopf-1 변이체 항체 및 사용 방법 | |
| IL316368A (en) | Anti-TL1A antibodies and methods of using them | |
| DK4073098T3 (da) | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse | |
| IL286811A (en) | Compositions and methods for stabilizing protein-containing formulations | |
| IL311638A (en) | Compositions and methods for treating cag repeat diseases | |
| IL315845A (en) | Anti-dectin-1 antibodies and methods of using them | |
| IL304607A (en) | Compositions comprising pedf-derived short peptides (pdsp) and uses thereof | |
| IL314210A (en) | CD47/PD-L1-targeted protein complex and methods of using it | |
| EP4387979A4 (en) | SINGLE-MOLECULE PROTEIN AND PEPTIDE SEQUENCING | |
| EP4065161A4 (en) | HIGH CONCENTRATION FORMULATIONS OF ANTI-CSF1 AND ANTI-CSF1R ANTIBODIES | |
| IL317690A (en) | Anti-GPNMB antibodies and methods of using them | |
| IL280261A (en) | Protein encapsulation of nutritional and pharmaceutical compositions | |
| IL280366A (en) | Methods of determining protein or peptide concentration and uses thereof |